Currently Viewing:
Currently Reading
How Does Underinsurance Impact Decision Making in Patients With Cancer?
August 11, 2017 – Surabhi Dangi-Garimella, PhD
Vaccine for Glioblastoma Awarded Orphan Drug Status by FDA
August 10, 2017 – Christina Mattina
Results of Phase 2 Study Investigating Luspatercept in MDS
August 09, 2017 – Alison Rodriguez
Study Investigates Molecular Profiling for Patients With Pancreatic Cancer
August 09, 2017 – Alison Rodriguez
Research Aims to Explain Paclitaxel's Ability to Both Treat and Spread Cancer
August 08, 2017 – Christina Mattina
Targeted Oral Anticancer Agents and the Part D Donut Hole: Need for a New Policy Strategy?
August 07, 2017 – Surabhi Dangi-Garimella, PhD
NCI Researchers Discuss Prospects and Challenges of Treating Glioblastoma
August 07, 2017 – Christina Mattina
5 Developments With Cancer Immunotherapy
August 04, 2017 – Surabhi Dangi-Garimella, PhD
Posttreatment Care in Breast Cancer: Oncologist vs PCP Roles
August 03, 2017 – Surabhi Dangi-Garimella, PhD

How Does Underinsurance Impact Decision Making in Patients With Cancer?

Surabhi Dangi-Garimella, PhD
A study in JAMA Oncology has found that unpreparedness for treatment-related expenses among patients being treated for cancer can bear upon the patientís future decision-making.
Underinsured patients are a growing population and with coverage policies remaining an unknown, financial stress could negatively impact patient decisions about their treatment. With this in mind, authors at Duke University conducted a survey at their cancer center and at 3 affiliated rural oncology clinics.


The cross-sectional study evaluated financial distress and cost expectations in patients who were receiving anticancer treatment. Patients were compensated $10 for participating on the survey. In addition to patient demographic information, data from their electronic health record was abstracted for cancer diagnosis, stage, and type and duration of treatment. Patients were queried on whether their costs met their expectations and on how much they were willing to pay out-of-pocket (OOP) for their cancer treatment (minus their insurance premium).


Of the 300 eligible patients, a little more than half were men (n = 157) and the mean age of the entire cohort was 59.6 years. A majority were white (n = 226), most held private insurance (n = 168), and a significant number earned less than $60,000 annually. The median monthly OOP cost for the group was $592, and more than half of the participants (n = 162) had advanced stage cancer at enrollment.


The study found that the relative cost of care for patients with high or overwhelming distress was 31%, compared with 10% for those who had no, low, or average financial distress. About 39% of patients (n = 118) endorsed they had a higher than expected financial burden from cancerĖa factor that was associated with being young, unmarried, nonwhite, unemployed/not retired, lower household income, higher costs, colorectal/breast cancer diagnosis, lower quality of life, and higher financial distress.


The analysis showed that financial burden was significantly associated with financial distress and a reduced willingness to pay for care. More than a third of insured patients in the group faced OOP costs much greater than what they had anticipated, and the underinsured, who were the most distressed, were paying almost a third of their income in healthcare-related costs.


The authors conclude that unexpected treatment costs were associated with a lower willingness to pay for care; so, unpreparedness for treatment-related expenses can bear upon the patientís future decision-making. They recommend interventions to improve patient literacy around healthcare costs as a path forward to mitigate costs through shared decision making.


The study has been published in JAMA Oncology.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up